Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.40 |
| ▸ | GABRE | P78334 | 1/20 | 0.40 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.40 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.40 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.40 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 6/20 | 0.38 |
| ▸ | CSF1R | P07333 | 11/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 10/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21408156 | 0.85 | TGFBR1 (0.37) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL21408154 | 0.83 | TGFBR1 (0.37) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL27116699 | 0.80 | TGFBR1 (0.35) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL16038352 | 0.78 | TGFBR1 (0.48) | TGFBR1CSF1RPDGFRAPDGFRBMET | |
| SCHEMBL16037107 | 0.77 | TGFBR1 (0.45) | TGFBR1CSF1RPDGFRAPDGFRBMET | |
| SCHEMBL21425624 | 0.75 | KDR (0.50) | CSF1R | |
| SCHEMBL16059181 | 0.75 | CSF1R (0.55) | TGFBR1CSF1RPDGFRAPDGFRBMET | |
| SCHEMBL16028424 | 0.74 | SCN9A (0.43) | TGFBR1SCN5ASCN9A | |
| SCHEMBL28012733 | 0.73 | MAPK14 (0.37) | METSCN9A | |
| SCHEMBL21772013 | 0.73 | TGFBR1 (0.37) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3632907-B1 | N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2024-02-28 | — | — | EP | disclosed |
| US-11149021-B2 | N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-10-19 | — | — | US | disclosed |
| EP-3632907-A1 | N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2020-04-08 | — | — | EP | disclosed |
| US-20200071302-A1 | N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071302-A1 | N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | CSF1R, CSF3R, FAR1 | GABRP 1097/4885GABRD 480/4885GABRA1 268/4885 |
| US-11149021-B2 | N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof | CSF1R, CSF3R, FAR1 | GABRP 1097/4885GABRD 480/4885GABRA1 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.